{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:39:03Z","timestamp":1765726743037,"version":"3.48.0"},"reference-count":33,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Mercatus Center, George Mason University Fast Grants","award":["#2207"],"award-info":[{"award-number":["#2207"]}]},{"name":"UC Office of the President, Emergency COVID-19 Research Seed Funding","award":["R00RG3118"],"award-info":[{"award-number":["R00RG3118"]}]},{"name":"Mercatus Center, George Mason University Fast Grants","award":["#2005"],"award-info":[{"award-number":["#2005"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,12,3]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>SARS-CoV-2 enters cells using the ACE2 receptor. Medications that affect ACE2 expression or function such as angiotensin receptor blockers (ARBs) and ACE inhibitors (ACE-I) and metformin have the potential to counter the dysregulation of ACE2 by the virus and protect against viral injury. Here, we describe COVID-19 survival associated with ACE-I, ARB and metformin use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This is a hospital-based observational study of patients with COVID-19 infection using logistic regression with correction for pre-existing conditions and propensity score weighted Cox proportional hazards models to estimate associations between medication use and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Medical record data from the US Veterans Affairs (VA) were used to identify patients with a reverse transcription PCR diagnosis of COVID-19 infection, to classify patterns of ACE inhibitors (ACE-I), ARB, beta blockers, metformin, famotidine and remdesivir use, and, to capture mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>9532 hospitalised patients with COVID-19 infection followed for 60 days were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measure<\/jats:title>\n                    <jats:p>Death from any cause within 60 days of COVID-19 diagnosis was examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Discontinuation of ACE-I was associated with increased risk of death (OR: 1.4; 95% CI 1.2\u20131.7). Initiating (OR: 0.3; 95% CI 0.2\u20130.5) or continuous (OR: 0.6; 95% CI 0.5\u20130.7) ACE-I was associated with reduced risk of death. ARB and metformin associations were similar in direction and magnitude and also statistically significant. Results were unchanged when accounting for pre-existing morbidity and propensity score adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Recent randomised clinical trials support the safety of continuing ACE-I and ARB treatment in patients with COVID-19 where indicated. Our study extends these findings to suggest a possible COVID-19 survival benefit for continuing or initiating ACE-I, ARB and metformin medications. Randomised trials are appropriate to confirm or refute the therapeutic potential for ACE-I, ARBs and metformin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-050051","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T10:30:28Z","timestamp":1640946628000},"page":"e050051","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study"],"prefix":"10.1136","volume":"11","author":[{"given":"Arthur W","family":"Wallace","sequence":"first","affiliation":[{"name":"San Franciso Veterans Affairs Medical Center, San Francisco, CA, USA"},{"name":"Department of Anesthesiology and Perioperative Care, University of California, San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4571-4544","authenticated-orcid":false,"given":"Piera M","family":"Cirillo","sequence":"additional","affiliation":[{"name":"San Franciso Veterans Affairs Medical Center, San Francisco, CA, USA"},{"name":"Child Health and Development Studies, Public Health Institute, Oakland, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C","family":"Ryan","sequence":"additional","affiliation":[{"name":"San Franciso Veterans Affairs Medical Center, San Francisco, CA, USA"},{"name":"Department of Gastroenterology, University of California, San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nickilou Y","family":"Krigbaum","sequence":"additional","affiliation":[{"name":"San Franciso Veterans Affairs Medical Center, San Francisco, CA, USA"},{"name":"Child Health and Development Studies, Public Health Institute, Oakland, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusha","family":"Badathala","sequence":"additional","affiliation":[{"name":"San Franciso Veterans Affairs Medical Center, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A","family":"Cohn","sequence":"additional","affiliation":[{"name":"San Franciso Veterans Affairs Medical Center, San Francisco, CA, USA"},{"name":"Child Health and Development Studies, Public Health Institute, Oakland, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,12,31]]},"reference":[{"key":"2025121407372539000_11.12.e050051.1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection: origin, transmission, and characteristics of human coronaviruses","volume":"24","author":"Shereen","year":"2020","journal-title":"J Adv Res"},{"key":"2025121407372539000_11.12.e050051.2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1570"},{"key":"2025121407372539000_11.12.e050051.3","first-page":"39","article-title":"Short-term dexamethasone in Sars-CoV-2 patients","volume":"103","author":"Selvaraj","year":"2020","journal-title":"R I Med J"},{"key":"2025121407372539000_11.12.e050051.4","doi-asserted-by":"publisher","DOI":"10.1056\/NE-JMoa2007016"},{"key":"2025121407372539000_11.12.e050051.5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321852"},{"key":"2025121407372539000_11.12.e050051.6","doi-asserted-by":"crossref","unstructured":"Sen Gupta PS , Biswal S , Singha D . Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2. J Biomol Struct Dyn 2020:1\u20137.","DOI":"10.26434\/chemrxiv.12382265.v1"},{"key":"2025121407372539000_11.12.e050051.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.05.053"},{"key":"2025121407372539000_11.12.e050051.8","doi-asserted-by":"crossref","unstructured":"Magagnoli J , Narendran S , Pereira F . Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv 2020;2020.04.16.20065920.","DOI":"10.1101\/2020.04.16.20065920"},{"key":"2025121407372539000_11.12.e050051.9","doi-asserted-by":"crossref","unstructured":"Cao YC , Deng QX , Dai SX . Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence. Travel Med Infect Dis 2020;101647.","DOI":"10.1016\/j.tmaid.2020.101647"},{"key":"2025121407372539000_11.12.e050051.10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmsr2005760"},{"key":"2025121407372539000_11.12.e050051.11","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-0375"},{"key":"2025121407372539000_11.12.e050051.12","doi-asserted-by":"publisher","DOI":"10.3414\/me17-01-0051"},{"key":"2025121407372539000_11.12.e050051.13","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.87.5.e1"},{"key":"2025121407372539000_11.12.e050051.14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11684-020-0754-0","article-title":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection","volume":"14","author":"Zou","year":"2020","journal-title":"Front Med"},{"key":"2025121407372539000_11.12.e050051.15","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/307315","article-title":"Angiotensin-converting enzyme 2: the first decade","volume":"2012","author":"Clarke","year":"2012","journal-title":"Int J Hypertens"},{"key":"2025121407372539000_11.12.e050051.16","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00498.2016"},{"key":"2025121407372539000_11.12.e050051.17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jmv.25726","article-title":"Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2","volume":"92","author":"Liu","year":"2020","journal-title":"J Med Virol"},{"key":"2025121407372539000_11.12.e050051.18","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4594","article-title":"Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"2025121407372539000_11.12.e050051.19","doi-asserted-by":"crossref","DOI":"10.1038\/srep19840","article-title":"Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus","volume":"6","author":"Gu","year":"2016","journal-title":"Sci Rep"},{"key":"2025121407372539000_11.12.e050051.20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200581200"},{"key":"2025121407372539000_11.12.e050051.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit Care"},{"key":"2025121407372539000_11.12.e050051.22","doi-asserted-by":"publisher","DOI":"10.1038\/nature00786"},{"key":"2025121407372539000_11.12.e050051.23","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2020.04.004"},{"key":"2025121407372539000_11.12.e050051.24","doi-asserted-by":"crossref","unstructured":"Jarcho JA , Ingelfinger JR , Hamel MB . Inhibitors of the renin-angiotensin-aldosterone system and Covid-19. N Engl J Med 2020.","DOI":"10.1056\/NEJMe2012924"},{"key":"2025121407372539000_11.12.e050051.25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025121407372539000_11.12.e050051.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.25864"},{"key":"2025121407372539000_11.12.e050051.27","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1515"},{"key":"2025121407372539000_11.12.e050051.28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22399"},{"key":"2025121407372539000_11.12.e050051.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0331-4"},{"key":"2025121407372539000_11.12.e050051.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.04.009"},{"key":"2025121407372539000_11.12.e050051.31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.mce.2017.09.025","article-title":"Metformin improves obesity-associated inflammation by altering macrophages polarization","volume":"461","author":"Jing","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"2025121407372539000_11.12.e050051.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101425","article-title":"ACE2, metformin, and COVID-19","volume":"23","author":"Malhotra","year":"2020","journal-title":"iScience"},{"key":"2025121407372539000_11.12.e050051.33","doi-asserted-by":"crossref","DOI":"10.26633\/RPSP.2020.40","article-title":"Clinical trials on drug repositioning for COVID-19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"Rev Panam Salud Publica"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-050051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:37:38Z","timestamp":1765726658000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-050051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,31]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/bmjopen-2021-050051"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-050051","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}